Supplemental information (Tables)

3 Months Ended

Nov. 30, 2021

Supplemental Cash Flow Elements [Abstract]

Schedule of Depreciation and Amortization Expense

The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

	Three months ended November 30,
	2021		2020
Depreciation expense	$	335	$	342
Intangible asset and other amortization	165		95
Total depreciation and amortization expense	$	500	$	437

Restrictions on Cash and Cash Equivalents

The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):

	November 30, 2021		August 31, 2021
Cash and cash equivalents - continuing operations	$	4,135	$	1,193
Restricted cash - continuing operations (included in other current assets)	133		77
Cash, cash equivalents and restricted cash	$	4,268	$	1,270

Schedule of Cash and Cash Equivalents

The following represents a reconciliation of cash and cash equivalents in the Consolidated Condensed Balance Sheets to total cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows (in millions):

	November 30, 2021		August 31, 2021
Cash and cash equivalents - continuing operations	$	4,135	$	1,193
Restricted cash - continuing operations (included in other current assets)	133		77
Cash, cash equivalents and restricted cash	$	4,268	$	1,270

Schedule of Redeemable Noncontrolling Interest

The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):

Redeemable noncontrolling interest roll forward:	Walgreens Boots Alliance, Inc.
August 31, 2021	$	319
Acquisitions 1	2,489
Net (loss)	(21)
Redemption value adjustment	7
Currency translation adjustments and other	(8)
November 30, 2021	$	2,787

1 Includes $1.9 billion of redeemable non-controlling interest representing the maximum purchase price to redeem non-controlling units in VillageMD for cash. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. As of November 30, 2021, the Company recorded the $1.9 billion as redeemable non-controlling interest. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement.

Schedule of Dividends Payable

Cash dividends per common share declared were as follows:

Quarter ended	2021		2020
November	$	0.4775	$	0.4675